GLP-1 Shortage 2024: Supply Issues & Access Solutions

Last reviewed: May 25, 2026

Last updated: May 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 medication availability has fluctuated significantly since 2023, driven by manufacturing demand, regulatory adjustments, and global supply chain factors. Recent reports indicate improved supply for major branded formulations, though some regions and dosage strengths remain subject to periodic constraints, making informed alternative planning clinically prudent.

For patients seeking GLP-1 therapy, understanding both branded and compounded pathways—along with genetic predisposition factors—enables more strategic conversations with providers. Personalized approaches consider individual biomarker profiles, medication tolerance patterns, and access constraints to optimize treatment selection and adherence.

The GLP-1 Supply Timeline and Current Market Status

Shortages peaked in late 2023 when semaglutide demand exceeded manufacturing capacity, forcing prescribers to implement prioritization protocols. By mid-2024, branded semaglutide and tirzepatide production increased substantially, though certain dosage strengths and formulations experienced intermittent delays. Current supply stability remains uneven across regions and retail channels.

Compounded GLP-1 medications offer a complementary access pathway. Licensed 503A compounding pharmacies can prepare semaglutide and tirzepatide formulations when branded supplies face constraints, though compounded versions differ from FDA-approved counterparts in manufacturing oversight and clinical trial data. Healthcare providers should evaluate both options based on patient-specific needs and local availability.

Factors Contributing to GLP-1 Availability Challenges and Solutions

Multiple systemic factors influenced GLP-1 supply dynamics: unprecedented demand surge from diabetes and weight-loss indications, specialized manufacturing requirements for injectable formulations, regulatory approval delays for new production facilities, and competing global demand. Understanding these drivers helps patients anticipate future constraints and plan proactively with their providers.

Supply Factor	Impact on Availability	Patient Consideration
Manufacturing capacity expansion	Gradual increase through 2024-2025; branded facilities adding production lines	Supply expected to stabilize; allow 2-4 weeks for new facility ramp-up
Dosage strength prioritization	Lower doses (0.25–0.5 mg) prioritized over maintenance doses initially	Titration protocols may extend; discuss timing with provider
Compounded pharmacy network	503A facilities can formulate semaglutide/tirzepatide when branded delayed	Compounded products cost 20-40% less; different regulatory pathway
Regional distribution variance	Urban/hospital systems received supplies faster than rural pharmacies	Check availability at local pharmacy; ask provider about alternatives

Evaluating Branded vs. Compounded GLP-1 Options During Supply Transitions

Branded medications (Ozempic, Mounjaro, Saxenda) undergo FDA review with extensive clinical trial data supporting efficacy and safety profiles. Compounded semaglutide and tirzepatide prepared in licensed 503A pharmacies cost less and address access gaps, but reflect different manufacturing standards. Providers should weigh clinical evidence, patient tolerance history, and cost-benefit when supply uncertainty exists.

Switching between branded and compounded formulations requires medical oversight. Bioavailability, injection technique, and storage protocols may differ slightly. Patients considering this transition should consult their provider about monitoring parameters, potential dose adjustments, and adverse event tracking to ensure continuity of care during any formulation change.

Genetic and Biomarker Context for Personalized GLP-1 Pathway Selection

Individual genetic variation in GLP-1 receptor signaling (GLP1R variants like rs6923761), GIPR pathway genes (rs1800437), and metabolic regulators (FTO rs9939609, MC4R rs17782313) may influence medication tolerance, efficacy perception, and side-effect profiles. Understanding these predispositions can support provider conversations about which GLP-1 formulation and dosing strategy may align with individual biology.

The Precision Peptide Genetic Test evaluates predispositions in these peptide pathway genes to provide clinical context for personalized GLP-1 selection. Testing may help clarify whether genetic factors contribute to prior treatment responses, inform dose timing or frequency preferences, and guide medication choice when supply forces treatment adjustments. Results should be interpreted with a qualified healthcare provider as part of comprehensive treatment planning.

Safety Considerations and Who Should Reassess GLP-1 Options During Supply Disruptions

Patients already stable on GLP-1 therapy should maintain their current regimen if possible; switching during controlled conditions with provider oversight minimizes adverse event risk. Patients new to GLP-1 initiation may benefit from compounded formulations to reduce cost and access delay, though they should expect similar titration protocols and monitoring as branded versions. Contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2) remain absolute regardless of formulation source.

Healthcare providers should counsel patients about realistic timelines, potential side effects (nausea, injection-site reactions, dehydration risk), and monitoring needs before supply transitions. Pregnancy, severe renal impairment, and gastroparesis represent key safety considerations requiring individualized risk-benefit discussion. Open provider communication about access barriers—cost, availability, preference—supports better adherence and clinical outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that GLP-1 supply variability combined with individual genetic predispositions creates opportunity for more strategic, personalized treatment planning. Genetic insights into peptide pathway function may help provide context for why certain formulations, dosages, or timing protocols resonate better for specific patients. This information can support a more informed conversation with your provider about matching your treatment approach to both your biology and your current access landscape.

The Precision Peptide Genetic Test reveals predispositions in key GLP-1 signaling genes (GLP1R, GIPR, FTO, MC4R) and metabolic regulators that may influence your individual response patterns. Testing does not predict exact medication response or guarantee outcomes, but can clarify whether genetic variation in these pathways may contribute to prior treatment experiences. This context becomes particularly valuable when considering formulation transitions or dosage adjustments during supply constraints.

If you're facing GLP-1 supply access challenges or considering a transition between branded and compounded formulations, combining genetic predisposition insights with provider guidance can optimize your selection strategy. PlexusDx compounded options—semaglutide, tirzepatide, and dual-compound protocols—range from $129-$369/mo through licensed 503A pharmacies. A qualified healthcare provider, informed by your genetic and clinical context, remains essential for safe, effective treatment planning during any medication adjustment.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.